Combination of PARP and ATR inhibitors (olaparib and ceralasertib) shows clinical activity in acquired PARP inhibitor-resistant recurrent ovarian cancer.

被引：20
|
作者：
Wethington, Stephanie L.
Shah, Payal D.
Martin, Lainie P.
Tanyi, Janos Laszlo
Latif, Nawar A.
Morgan, Mark Aloysuis
Torigian, Drew A.
Pagan, Cheyenne
Rodriguez, Diego
Domchek, Susan M.
Drapkin, Ronny
Shih, Le-Ming
Smith, Simon
Dean, Emma
Armstrong, Deborah Kay
Gaillard, Stephanie
Simpkins, Fiona
机构：
[1] Johns Hopkins Univ, Baltimore, MD USA
[2] Univ Penn, Philadelphia, PA 19104 USA
[3] Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA
[4] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA
[5] Hosp Univ Penn, Radiol, 3400 Spruce St, Philadelphia, PA 19104 USA
[6] Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA
[7] Dana Farber Canc Inst, Boston, MA 02115 USA
[8] AstraZeneca, Cambridge, England
[9] Univ Manchester, Manchester, Lancs, England
[10] Christie NHS Fdn Trust, Manchester, Lancs, England
[11] Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA
[12] Johns Hopkins Sch Med, Baltimore, MD USA
[13] Univ Penn, Sch Med, Philadelphia, PA 19104 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 15期
关键词：
D O I：
10.1200/JCO.2021.39.15_suppl.5516
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5516
引用
下载
收藏
页数：3
相关论文
共 50 条
  • [31] Selinexor, a selective inhibitor of nuclear export (SINE) compound, shows enhanced antitumor activity in combination with the PARP inhibitor, olaparib, in models of triple-negative breast cancer
    Marijon, Helene
    Gery, Sigal
    Elloul, Sivan
    Friedlander, Sharon Y.
    Unger, T. J.
    Carlson, Robert
    Shacham, Sharon
    Kauffman, Michael
    Koeffler, Harold P.
    CANCER RESEARCH, 2015, 75
  • [32] ATR inhibition disrupts rewired homologous recombination and fork protection pathways in PARP inhibitor-resistant BRCA-deficient cancer cells
    Yazinski, Stephanie A.
    Comaills, Valentine
    Buisson, Remi
    Genois, Marie-Michelle
    Nguyen, Hai Dang
    Ho, Chu Kwen
    Kwan, Tanya Todorova
    Morris, Robert
    Lauffer, Sam
    Nussenzweig, Andre
    Ramaswamy, Sridhar
    Benes, Cyril H.
    Haber, Daniel A.
    Maheswaran, Shyamala
    Birrer, Michael J.
    Zou, Lee
    GENES & DEVELOPMENT, 2017, 31 (03) : 318 - 332
  • [33] Phase I expansion of olaparib (PARP inhibitor) and AZD5363 (AKT inhibitor) in recurrent ovarian, endometrial and triple negative breast cancer
    Westin, S.
    Litton, J.
    Williams, R.
    Soliman, P.
    Frumovitz, M.
    Schmeler, K.
    Jazaeri, A.
    Sood, A.
    Lu, K.
    Moulder, S.
    Murthy, R.
    Rodriguez, A.
    Samuel, C.
    Engerman, L.
    Cyriac, A.
    Rugman, P.
    Lindemann, J.
    McMurtry, E.
    Mills, G.
    Coleman, R.
    ANNALS OF ONCOLOGY, 2017, 28
  • [34] ANTITUMOUR ACTIVITY OF THE PARP INHIBITOR OLAPARIB IN UNSELECTED SPORADIC CASTRATION-RESISTANT PROSTATE CANCER (CRPC) IN THE TOPARP TRIAL
    Mateo, J.
    Hall, E.
    Sandhu, S.
    Omlin, A. G.
    Miranda, S.
    Carreira, S.
    Goodall, J.
    Gillman, A.
    Mossop, H.
    Ralph, C.
    Zafeiriou, Z.
    Lopez, R. Perez
    Tunariu, N.
    Ferraldeschi, R.
    Rodrigues, D. Nava
    Kunju, L. P.
    Robinson, D.
    Attard, G.
    Chinnaiyan, A.
    de Bono, J. S.
    ANNALS OF ONCOLOGY, 2014, 25
  • [35] A phase 1 trial of the PARP inhibitor fuzuloparib in combination with the anti-angiogenic apatinib in recurrent ovarian or triple-negative breast cancer.
    Li, Huiping
    Zhang, Jiayang
    Yin, Rutie
    Song, Nan
    Zhang, Youzhong
    Zhang, Yu
    Zhang, Keqiang
    Pan, Hongming
    Wang, Ke
    Lou, Ge
    Li Guiling
    Zhang, Ben
    Wang, Quanren
    Gao, Yunong
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [36] Efficacy and Safety of PARP Inhibitor Combination Therapy in Recurrent Ovarian Cancer: A Systematic Review and Meta-Analysis
    Ren, Ning
    Zhang, Leyin
    Yu, Jieru
    Guan, Siqi
    Dai, Xinyang
    Sun, Leitao
    Ying, Minli
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [37] Pre-clinical combination of a PARP inhibitor, talazoparib, and carboplatin in triple-negative breast cancer.
    Cotte, Alexia
    Beniey, Michele
    Haque, Takrima
    Bechir, Nelly
    Hubert, Audrey
    Diallo, Korotoum W.
    Tran-Thanh, Danh
    Hassan, Saima N.
    CANCER RESEARCH, 2021, 81 (13)
  • [38] Nuclear export inhibitor KPT-8602 synergize with PARP inhibitors in castration resistant metastatic prostate cancer.
    Uddin, Md. Hafiz
    Li, Yiwei
    Aboukameel, Amro
    Khan, Husain Y.
    Singh, Vijendra
    Reddy, Shriya
    Balasubramanian, Suresh Kumar
    Landesman, Yosef
    Kashyap, Trinayan
    Heath, Elisabeth I.
    Azmi, Asfar S.
    CANCER RESEARCH, 2021, 81 (13)
  • [39] Cell cycle checkpoints and beyond: Exploiting the ATR/CHK1/WEE1 pathway for the treatment of PARP inhibitor-resistant cancer
    Gupta, Nitasha
    Huang, Tzu-Ting
    Horibata, Sachi
    Lee, Jung-Min
    PHARMACOLOGICAL RESEARCH, 2022, 178
  • [40] Life after SOLO-2: is olaparib really inducing platinum resistance in BRCA-mutated (BRCAm), PARP inhibitor (PARPi)-resistant, recurrent ovarian cancer?
    Kristeleit, R. S.
    Moore, K. N.
    ANNALS OF ONCOLOGY, 2022, 33 (10) : 989 - 991
12345